Clinical Trial Update: Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab plus chemotherapy versus chemotherapy as perioperative treatment in HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: HER2-negative Breast Cancer | Phase 2 | Status: UNKNOWN